Children's Hospital is part of the UPMC family.
Be safe anytime, anywhere.
To find a pediatrician or pediatric specialist, please call 412-692-7337 or search our directory.
A resource for our network of referring physicians.
For more information about research, please call our main office at 412-692-6438.
Children's Hospital is ranked One of America's Best Children's Hospitals.
Through clinical trials, the Pediatric Hematology/Oncology team at Children's Hospital of Pittsburgh of UPMC is accelerating the search for cures to childhood cancer. Collaborating closely with the Children’s Oncology Group (COG), the only pediatric oncology clinical trials group funded by the National Cancer Institute and National Institutes of Health, Children’s is among an elite group of hospitals participating in Phase I clinical trials through COG and the Pediatric Brain Tumor Consortium.
To help you locate a study relevant to your interests, we have organized them below.
Simply select a category and then browse the studies within the category to review brief descriptions and requirements. Or if you are looking for a study dealing with a specific condition, please use the search tool at the top of this page. Be sure to include the word "study" along with the name of the condition. Physicians or parents/guardians of pediatric patients who might be eligible are encouraged to inquire about enrollment. Contact information is listed at the end of each study.
Children’s Hospital of Pittsburgh of UPMC is one of only 21 hospitals qualified to be part of the Children’s Oncology Group’s elite Phase I/Pilot Research Consortium.
Phase I drug studies are the most experimental in nature, and therefore are conducted with the smallest groups of volunteers. They are initiated after drugs have passed animal and cell studies, and are offered to those children for whom standard care and other clinical studies have already failed. Although Phase I experimental therapeutics present hope for such situations, as with any experimental treatment, there are no guarantees.
Quality of life, especially at this stage of treatment, is a top priority for Children’s medical and research team members, who are acutely tuned to the needs of patients and their families. Families who come from outside the Greater Pittsburgh region may incur travel costs. For Phase I studies in particular, Children’s can help through support it receives from Alex’s Lemonade Stand Foundation. Lodging for family members may be provided through the Ronald McDonald House.
Children’s studies in hematology and oncology are organized according to the seven groups listed below, and Pilot and Phase I clinical trials are labeled within each grouping for easy identification.
Simply select a category and then browse the studies within the category to review brief descriptions and requirements. Physicians or parents/guardians of pediatric patients who might be eligible are encouraged to inquire about enrollment. Contact information is listed at the end of each study.
Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk B-Acute Lymphoblastic Leukemia or localized B-Lineage Lymphoblastic Lymphoma
Proper Protocols for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Trial for Patients with de novo Acute Myeloid Leukemia using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD
Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia using Arsenic Trioxide and All Trans-Retinoic Acid
Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma
Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors
A Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors
Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma
MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma
Treatment for Recurrent Ependymomas in Children Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod
A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
Adding the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Children with Recurrent Unresectable Low-Grade Gliomas (LGG)
Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas
Treatment of Newly Diagnosed Brainstem Gliomas and Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade and High-Grade Gliomas
Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia, Testing Clofarabine in the Very High Risk Stratum
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
Brentuximab Vedotin in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent, in Children with Refractory or Recurrent Solid Tumors including Lymphomas
Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma or Mature B-cell Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab) in Combination with GM-CSF (Sargramostim) in Patients with Recurrent Osteosarcoma
A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Specimens Including Rare Pediatric Tumors
Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Peginterferon alfa-2b in Treating Young Patients with Unresectable, Sympotomatic or Life-Threatening Plexiform Neurofibromas Associated with Neurofibromatosis Type 1
A Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease
A Study of Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease
Patient-Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease Modifying Therapy with Hydroxyurea in Patients with Sickle Cell Disease
Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises (SUSTAIN)
Evaluation of Purified Poloxamer 188 (MST 188) in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Pazopanib Neoadjuvunt Trial on Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
MK-1775 in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
A Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
Bortezomib on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Biology Study of Transient Myeloproliferative Disorder in Children with Down Syndrome
BMN 673, an Oral Poly Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies
Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
Children’s Hospital of Pittsburgh of UPMC
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to: